Spravato Reimbursement in Switzerland: 2026 Guide

Yes, with conditions. Since 1 October 2025, Swiss basic insurance (OKP) reimburses esketamine nasal spray (Spravato) for severe treatment-resistant depression — but only at the 52 BAG-designated centers, only after your insurer's trust doctor approves a cost request, and for a maximum of 10 months. Switzerland runs one of Europe's strictest pre-approval models, so the criteria and the paperwork matter more here than almost anywhere else. This page covers exactly who qualifies, how the pre-approval works, what you pay, and the routes if you fall outside the Limitatio; the eligibility decision itself always sits with a clinician, and you can begin orienting yourself with our eligibility check.

What is covered

Spravato entered the Spezialitätenliste on 1 October 2025 with temporary limitations running to 30 September 2028, under a strict Limitatio. Basic insurance covers treatment only at the 52 centers designated by the BAG — institutions with a cantonal mandate for adult psychiatric care. Coverage runs for a maximum of 10 months, extendable at most twice by 3 months each when continued response is documented, and esketamine is always used in combination with an oral antidepressant.

Who qualifies

The Limitatio, per the BAG listing documentation and the standard insurer request form, requires:

Age 18–74 with a severe treatment-resistant episode of major depression;
Failure of at least 2 different antidepressants plus 1 augmentation attempt (lithium or an atypical antipsychotic) at adequate dose and duration;
Severity of CGI-S 5 or higher;
Electroconvulsive therapy currently not indicated, refused, or not accessible;
Use in combination with an oral antidepressant.

Every one of these points is read against your documented treatment history, so the most useful preparation is a written list of every antidepressant and augmentation tried, with substance, dose, duration and outcome — in a pre-approval system, this record is literally what the insurer's physician reads.

Who decides and how to apply

Prescribing is restricted to psychiatrists at the 52 designated centers. Before the first dose, the center submits a cost approval request (Kostengutsprache) to your insurer, reviewed by the trust doctor (Vertrauensarzt), who checks your documented history against the Limitatio. Practically: ask your psychiatrist for a referral to the nearest listed center, bring a complete medication history, and budget some weeks for the pre-approval step — and ask the center to start it early. Because coverage is time-capped, discuss the maintenance and exit strategy at the start, not at month nine. To see who is listed near you, browse providers in Switzerland; for the full picture of every legal route, including the limited medical use program for psilocybin, LSD and MDMA, see our Switzerland access guide.

What it costs you

Once the trust doctor approves, treatment at a designated center is covered by basic insurance (OKP) for the capped period. The comparison with the alternatives is stark: private off-label ketamine runs roughly CHF 300–500 per infusion, entirely self-pay — a request to add ketamine to the reimbursement annex for depression and pain was rejected — and psilocybin, LSD or MDMA treatment under the limited medical use program is usually self-paid, since those substances are not on the Spezialitätenliste.

If you do not qualify

Art. 71a–d KVV — individual-case reimbursement. Swiss insurers can cover medicines outside the approved list for serious disease with high expected benefit and no alternative. This is the realistic route for esketamine outside the Limitatio — over 74, or beyond the 10-month cap; its use for authorized MDMA, LSD or psilocybin therapy is theoretically arguable but not documented in practice. Success is case-by-case and needs a specialist willing to argue your file.
Private off-label ketamine at roughly CHF 300–500 per infusion, self-pay. Verify the physician's authorization and apply the checks in our clinic-choice guide — psychiatric and cardiovascular screening before payment, a physician present, measured outcomes.
Clinical trials are free by definition, and the Swiss scene — anchored by Basel and Zurich — is one of Europe's densest; see the trials guide.

Frequently asked questions

Is Spravato reimbursed in Switzerland?

Yes — since 1 October 2025 basic insurance covers it for severe treatment-resistant depression, but only at the 52 BAG-designated centers, only after your insurer's trust doctor approves a cost request, and for a maximum of 10 months, extendable at most twice by 3 months.

I am over 74, or my 10 months are up — is that final?

Not necessarily. Art. 71a–d KVV lets insurers reimburse individual cases outside the Limitatio for serious disease with high expected benefit and no alternative — realistic for esketamine beyond the age or time limits, but case-by-case and dependent on a supportive specialist.

Do I have to try ECT before Spravato is covered?

No — the Limitatio requires that ECT is currently not indicated, is refused by you, or is not accessible. Your psychiatrist documents which applies.

Is psilocybin, LSD or MDMA therapy covered?

No. Switzerland's limited medical use program makes those treatments legally available through authorized physicians, but they are not on the Spezialitätenliste and are usually self-paid. Switzerland is still one of the stricter pre-approval systems for esketamine — see the Europe-wide reimbursement map for how it compares.

Sources

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and reimbursement rules change; always verify current requirements with your insurer and discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

This guide awaits review by a licensed medical professional.

Is Esketamine (Spravato) Reimbursed in Switzerland? 2026 Coverage Guide

On this page